HoyleCohen’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
$536K Hold
1,100
0.04% 183
2024
Q1
$594K Sell
1,100
-200
-15% -$109K 0.05% 187
2023
Q4
$722K Hold
1,300
0.06% 169
2023
Q3
$568K Sell
1,300
-100
-7% -$49.9K 0.05% 173
2023
Q2
$703K Hold
1,400
0.06% 161
2023
Q1
$700K Hold
1,400
0.07% 158
2022
Q4
$571K Hold
1,400
0.06% 175
2022
Q3
$456K Sell
1,400
-300
-18% -$110K 0.05% 179
2022
Q2
$596K Hold
1,700
0.06% 168
2022
Q1
$930K Hold
1,700
0.08% 146
2021
Q4
$1.12M Hold
1,700
0.09% 138
2021
Q3
$1.06M Hold
1,700
0.1% 133
2021
Q2
$1.07K Hold
1,700
0.08% 136
2021
Q1
$832K Hold
1,700
0.08% 148
2020
Q4
$850K Hold
1,700
0.1% 132
2020
Q3
$668K Hold
1,700
0.1% 122
2020
Q2
$561K Hold
1,700
0.09% 122
2020
Q1
$412K Hold
1,700
0.08% 133
2019
Q4
$444K Hold
1,700
0.07% 147
2019
Q3
$462K Hold
1,700
0.08% 144
2019
Q2
$468K Hold
1,700
0.08% 140
2019
Q1
$380K Hold
1,700
0.07% 145
2018
Q4
$316K Hold
1,700
0.06% 141
2018
Q3
$424K Hold
1,700
0.08% 129
2018
Q2
$370K Buy
+1,700
New +$350K 0.07% 134

Other funds holding IDXX

HoyleCohen's IDXX Position: Q2 2024 in Review

HoyleCohen held its Idexx Laboratories (IDXX) position steady in Q2 2024 at 1,100 shares worth $536K. The position accounts for 0.04% of the portfolio, ranked #183.

HoyleCohen first reported a position in IDXX in Q2 2018 and has held it in 25 quarters since. The position peaked at $1.12M in Q4 2021. 1,109 funds tracked by Wall St. Rank hold IDXX as of Q2 2024.

  • HoyleCohen held 1,100 shares of Idexx Laboratories worth $536K as of Q2 2024.
  • HoyleCohen left its Idexx Laboratories share count unchanged in Q2 2024.
  • Idexx Laboratories made up 0.04% of HoyleCohen's portfolio in Q2 2024, its #183 holding.
  • HoyleCohen first reported a position in Idexx Laboratories in Q2 2018 and has held it in 25 quarters since.
  • HoyleCohen's Idexx Laboratories position peaked at $1.12M in Q4 2021.
  • 1,109 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2024.

Based on HoyleCohen's 13F filing for Q2 2024, filed 19 Jul 2024.